Compare Innodata Inc (INOD) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innodata Inc vs Revvity Inc — how do they compare? Innodata Inc trades at $62.04 (market cap $2.10B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 8.1× Innodata Inc's market cap, and Revvity Inc pays a 0.18% dividend while Innodata Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Innodata Inc for 19 Days and Revvity Inc for 12 Days on average.
| INOD | RVTY | |
|---|---|---|
Market Cap | $2.10B | $16.98B |
Volume | 989,493 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $121.50 | $157.36 |
52-Week Low | $34.45 | $82.26 |
Typical Hold Time | 19 Days | 12 Days |
Enterprise Value | $1.86B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INOD is trading at $61.20, down 3.49% today, showing bearish technical signals despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters with Q1 2026 EPS of $0.42 versus $0.13 expected. Revenue growth accelerated from $252M in 2025 to $317M in 2026, while net profit margins improved from 12.78% to 14.65%. Recent developments include the opening of a motion-capture AI lab and board appointments strengthening cybersecurity expertise.
The stock presents a growth opportunity with strong AI data engineering positioning and expanding margins, but faces headwinds from premium valuation (P/E 47.43) and technical weakness. Key risks include customer concentration and competitive pressures in the AI services sector. Analyst consensus remains bullish with 4 buy ratings versus 2 holds, suggesting potential upside if execution continues.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Innodata Inc
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
